Bio pharmaceutical enterprises benefited significantly from the release of the recommendation guidelines for the listing of science and Technology Innovation Board

[chinapharma.com pharmaceutical stock market] on March 3, Shanghai Stock Exchange issued the recommendation guidelines for the listing of science and technology innovation board enterprises of Shanghai Stock Exchange (hereinafter referred to as the "guidelines") Article 3 of the guidelines states that the recommendation agencies shall give priority to the following enterprises: scientific and technological innovation enterprises that conform to the national strategy, break through key core technologies and have high market recognition; Second, scientific and technological innovation enterprises belong to the new generation of information technology, advanced equipment, new materials, new energy, energy conservation and environmental protection, bio medicine and other high-tech industries and strategic emerging industries; third, scientific and technological innovation enterprises with deep integration of Internet, big data, cloud computing, artificial intelligence and manufacturing industries Among them, biomedicine mainly includes biological products, advanced chemical drugs, advanced medical equipment and devices and related technical services According to the insiders, considering the new scientific and technological attributes of long R & D cycle, high technical barriers, large R & D investment, high risk and high return in the pharmaceutical industry, "positioning new industries of scientific and technological innovation", "allowing unprofitable scientific and technological companies to declare and especially point out biomedical enterprises" are completely customized for scientific and technological innovation biomedical enterprises Therefore, innovative drugs, innovative medical devices enterprises with outstanding first-class market qualifications, enterprises participating in such companies in the second-class market and service providers in the innovative drug industry chain are expected to be the main beneficiaries of science and technology innovation board Industry insiders suggest focusing on the unmet clinical needs of internationally competitive small molecule innovative drugs, bio similar drugs, cell therapy, molecular diagnosis, innovative medical devices, etc In addition, in addition to the bio pharmaceutical technology companies that directly intend to apply for the science and technology innovation board and the listed companies that share in the technology innovation board, the innovation direction of the pharmaceutical sector is expected to get the risk preference improvement and valuation impact of the whole bank In terms of pharmaceutical stock market, on March 4, the Shanghai stock index of a share broke through 3000 points, and pharmaceutical stocks became active again, which led to the rise and fall of Weiming pharmaceutical, Longjin pharmaceutical, Kanghong pharmaceutical, Beilu pharmaceutical, magic pharmaceutical and other stocks It is expected that the detailed rules of the science and Technology Innovation Board will be issued and the valuation will be no less than 4 billion yuan It is required that at least one core product be approved to carry out two phase clinical trials, and there is no requirement for the current income and profit, reflecting a very strong value orientation of encouraging innovation In addition, on March 3, Shanghai Stock Exchange also released the question and answer on the examination and approval of the issuance and listing of science and technology innovation board shares of Shanghai Stock Exchange, which was approved by China Securities Regulatory Commission and implemented as of the date of issuance The following are listed: how to understand "other major illegal acts involving national security, public security, ecological security, production safety, public health and safety and other fields" in the issuance conditions? In the past three years, if the issuer, its controlling shareholder or actual controller has one of the following illegal acts in the fields of national security, public security, ecological security, production safety, public health and safety, it shall be regarded as a major illegal act in principle: being punished by fine and other penalties with serious circumstances; causing serious environmental pollution, major casualties, bad social impact, etc The issuer shall conform to the positioning of science and technology innovation board, and how to grasp it? When the issuer conducts self-evaluation, it shall respect the laws of science and technology innovation, capital market and enterprise development, and accurately understand and grasp the positioning of science and technology innovation board in combination with its own and Industry Science and technology innovation reality, and consider the following factors: (1) the matching degree of the industry and its technological development trend with the national strategy; (2) the position of the core technology owned by the enterprise in the development level at home and abroad; (3) the specific representation of the core competitiveness and its technological innovation level; (4) the specific arrangement of maintaining the mechanism, technological reserve and technological innovation of technological innovation; (5) The actual situation of production and operation relying on core technology "Listing review rules" stipulates that the issuer shall mainly rely on core technology to carry out production and operation How to understand this? Mainly relying on core technology to carry out production and operation means that the main business results of an enterprise come from products or services relying on core technology First, the issuer can adhere to scientific and technological innovation and form core technology through continuous R & D investment accumulation Second, the issuer's main production and operation can be based on the core technology, transform the achievements of the core technology, and form products (services) based on the core technology Third, the judgment of core technology is mainly based on the national science and technology development strategy and policy, overall technology level, domestic and foreign science and technology development level and trend of the issuer's industry.